Latest news with #FDCLtd
Business Upturn
29-05-2025
- Business
- Business Upturn
FDC shares drop over 3% as Q4 EBITDA falls 4.2% YoY to Rs 54 crore, net profit down 16.4% YoY
Shares of FDC Ltd dropped more than 3% following the release of its fourth-quarter financial results, which showed a mixed performance. Despite a moderate increase in revenue, profitability declined, weighing on investor sentiment. As of 10:17 AM, the shares were trading 3.49% lower at Rs 440.50. In the quarter ended March 2025, the company reported a consolidated revenue of ₹492 crore, a year-on-year growth of 6.5% compared to ₹462 crore in the same period last year. However, earnings before interest, tax, depreciation, and amortisation (EBITDA) fell by 4.2% to ₹54 crore from ₹56.3 crore. The EBITDA margin narrowed to 11% from 12.2% a year ago, indicating rising costs or pressure on operational efficiency. Net profit for the quarter came in at ₹38.7 crore, down 16.4% from ₹46.3 crore in the year-ago period. FDC shares opened at ₹445.00 today, and, at the time of writing, reached a high of ₹451.55 and a low of ₹435.10. The stock is currently trading well below its 52-week high of ₹658.85, yet above its 52-week low of ₹366.25. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Time of India
09-05-2025
- Health
- Time of India
FDC recalls over 60,000 bottles of ophthalmic solution in US
Drug firm FDC Ltd is recalling over 60,000 bottles of a generic medication, used to treat glaucoma, in the US market due to manufacturing issue, according to the US health regulator. As per the latest Enforcement Report by Food and Drug Administration (USFDA), the Mumbai-headquartered drug firm is recalling 60,428 bottles of Timolol Maleate Ophthalmic Solution in the US market. #Operation Sindoor India-Pakistan Clash Live Updates| Missiles, shelling, and attacks — here's all that's happening Pakistani Air Force jet shot down in Pathankot by Indian Air Defence: Sources India on high alert: What's shut, who's on leave, and state-wise emergency measures The company is recalling the affected lot due to "Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle," the USFDA said. The drugmaker initiated the Class II nationwide (US) recall on April 18 this year. As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Shares of FDC on Friday ended 0.31 per cent up at Rs 430 apiece on the BSE.
